AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment

Abbvie (ABBV) announced an update on their ongoing clinical study.

The phase 1 study, officially titled “A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab,” aims to see how AbbVie’s drug moves through the body in different dosing methods. It focuses on basic drug behavior in healthy adults, which supports longer term plans for safer, more convenient use.

The study tests risankizumab, a biologic drug already key to AbbVie’s immunology portfolio. It compares an intravenous infusion and a subcutaneous injection to see which route offers better, more predictable exposure for future clinical and commercial use.

This is an interventional phase 1 trial in healthy volunteers with randomized group assignment. It uses a simple parallel design with no blinding, so each group gets either IV or SC dosing, and the main goal is to understand how the drug is absorbed and cleared rather than to treat disease.

The study was first submitted on 2026-03-09, marking the official start of regulatory tracking. The same date is listed as the last update, and with status still “not yet recruiting,” timelines for primary and final completion will likely be set as site start up and enrollment planning firm up.

For investors, this update signals continued investment in risankizumab life cycle management, which can support ABBV’s long term cash flows as older drugs like Humira lose share. Improving dosing options could defend AbbVie’s position against rivals such as JNJ and Novartis in inflammatory diseases and may modestly support sentiment if execution stays on track.

The study is currently listed as not yet recruiting and remains an active, updated program, with further details available on the ClinicalTrials portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.